Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Gaia Sampogna, Filippo Caraci, Claudia Carmassi, Bernardo Dell’Osso, Silvia Ferrari, Giovanni Martinotti, Gabriele Sani, Gianluca Serafini, Maria Salvina Signorelli & Andrea Fiorillo. (2023) Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper. Expert Opinion on Pharmacotherapy 24:14, pages 1511-1525.
Read now
Read now
Trevor R Norman & James S Olver. (2021) Desvenlafaxine in the treatment of major depression: an updated overview. Expert Opinion on Pharmacotherapy 22:9, pages 1087-1097.
Read now
Read now
Articles from other publishers (11)
Manman Wang, Yingying Yang, Wei Hu, Yue Wang, Youli Chen & Xueyuan Zhang. (2023) The Pharmacokinetics and Bioequivalence of Desvenlafaxine Succinate in Chinese Healthy Subjects Under Fasting and Fed States. Clinical Pharmacology in Drug Development 12:7, pages 699-705.
Crossref
Crossref
Erick H. Turner, Andrea Cipriani, Toshi A. Furukawa, Georgia Salanti & Ymkje Anna de Vries. (2022) Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. PLOS Medicine 19:1, pages e1003886.
Crossref
Crossref
Chen Zhu, Xinwei Li, Weiqing Peng & Wei Fu. (2020) Discovery of Novel Indolealkylpiperazine Derivatives as Potent 5-HT1A Receptor Agonists for the Potential Future Treatment of Depression. Molecules 25:21, pages 5078.
Crossref
Crossref
Martin A Katzman, Xuemei Wang, Dalia B Wajsbrot & Matthieu Boucher. (2020) Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. Journal of Psychopharmacology 34:3, pages 280-292.
Crossref
Crossref
Caren Nádia Soares de Sousa, Lucas Nascimento Meneses, Germana Silva Vasconcelos, Ingridy da Silva Medeiros, Márcia Calheiros Chaves Silva, Fayçal Mouaffak, Oussama Kebir, Cláudio Manuel Gonçalves da Silva Leite, Manoel Cláudio Azevedo Patrocinio, Danielle Macedo & Silvânia Maria Mendes Vasconcelos. (2018) Neuroprotective evidence of alpha-lipoic acid and desvenlafaxine on memory deficit in a neuroendocrine model of depression. Naunyn-Schmiedeberg's Archives of Pharmacology 391:8, pages 803-817.
Crossref
Crossref
Alice I. Nichols, Sam Liao & Richat Abbas. (2018) Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations. Clinical Pharmacology in Drug Development 7:4, pages 441-450.
Crossref
Crossref
Raymond W Lam, Dalia B Wajsbrot, Ellen Meier, Elizabeth Pappadopulos, Joan A Mackell & Matthieu Boucher. (2017) Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis. Journal of Psychopharmacology 31:9, pages 1204-1214.
Crossref
Crossref
Shaila Misri, Elena Swift, Jasmin Abizadeh & Radhika Shankar. (2016) Overcoming functional impairment in postpartum depressed or anxious women: a pilot trial of desvenlafaxine with flexible dosing. Therapeutic Advances in Psychopharmacology 6:4, pages 269-276.
Crossref
Crossref
H. Javelot. (2016) Psychopharmacologie de l’anxiété et de la dépression : aspects historiques, traitements actuels et perspectives. Annales Pharmaceutiques Françaises 74:2, pages 93-118.
Crossref
Crossref
Márcia Calheiros Chaves Silva, Caren Nádia Soares de Sousa, Patrícia Xavier Lima Gomes, Gersilene Valente de Oliveira, Fernanda Yvelize Ramos Araújo, Naiara Coelho Ximenes, Jéssica Calheiros da Silva, Germana Silva Vasconcelos, Luzia Kalyne Almeida Moreira Leal, Danielle Macêdo & Silvânia Maria Mendes Vasconcelos. (2016) Evidence for protective effect of lipoic acid and desvenlafaxine on oxidative stress in a model depression in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, pages 142-148.
Crossref
Crossref
F. Franek, A. Jarlfors, F. Larsen, P. Holm & B. Steffansen. (2015) In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation. European Journal of Pharmaceutical Sciences 77, pages 303-313.
Crossref
Crossref